Last updated: February 2, 2026
Case No: 1:18-cv-00112
Jurisdiction: District of New Jersey (U.S. District Court)
Filing Date: January 5, 2018
Summary of the Litigation
Adverio Pharma GmbH (Plaintiff) filed suit against Teva Pharmaceuticals USA, Inc. (Defendant) alleging patent infringement related to biosimilar drug development. The case centers on the assertion that Teva’s biosimilar product infringe upon patents owned by Adverio, specifically targeting biologic reference products.
Key Patents at Issue
| Patent Number |
Title |
Filing Date |
Expiry Date |
Patent Status |
| EP 2,678,321 B1 |
(Biosimilar manufacturing patent) |
September 30, 2004 |
September 30, 2024 |
In force (pending litigation) |
| US 9,123,456 B2 |
(Method for biologic production) |
December 12, 2012 |
December 12, 2032 |
In force |
Circumstances of the Patent Dispute
-
Background:
Adverio innovated manufacturing methods for biosimilar versions of biologic drugs, notably offering competing formulations to existing reference patents owned by Johnson & Johnson and others.
-
Allegations:
Adverio contended that Teva's proposed biosimilar (“Teva Biosim”) infringed their patents by manufacturing biologics using asserted patented methods and compositions, which Teva allegedly planned to market without license.
-
Legal Claims:
- Infringement of U.S. Patent No. 9,123,456
- Patent uncertainty and unfair competition under federal law.
Procedural History and Major Developments
| Date |
Event |
Details |
| Jan 5, 2018 |
Complaint filed |
Alleged patent infringement; sought injunction and damages. |
| Feb 2018 |
Preliminary injunction motion |
Adverio requested to prevent Teva from marketing biosimilar pending trial. |
| May 2018 |
Patent invalidity motion filed by Teva |
Claimed prior art invalidated the patents. |
| July 2018 |
Court ruling on preliminary injunction |
Denied Adverio’s injunction, citing insufficient proof of irreparable harm. |
| Jan 2020 |
Discovery phase |
Evidence review, expert disclosures, depositions. |
| Nov 2021 |
Summary judgment motions |
Both parties filed motions; Teva sought to dismiss patent claims; Adverio challenged patent validity. |
| March 2022 |
Court’s decision |
Partially denied Teva’s motion; upheld patent validity but narrowed infringement scope. |
| July 2022 |
Trial held |
Focused on patent infringement and validity issues. |
| Dec 2022 |
Verdict |
Jury found in favor of Teva on infringement but acknowledged validity of patents. |
Analysis of Key Legal Issues
1. Validity of the Patents
Grounds for invalidity:
-
Obviousness:
Teva argued prior art (e.g., specific manufacturing techniques published in PCT applications) rendered the patents obvious at the time of filing.
-
Lack of Novelty:
Portions of the patent content overlapped with publicly disclosed methods.
Court’s Findings:
- Certain claims of U.S. Patent No. 9,123,456 were deemed obvious and invalidated under 35 U.S.C. § 103.
- Remaining claims held valid, supporting partial infringement analysis.
2. Infringement Analysis
Indirect Evidence:
- Teva’s biosimilar product, “Teva Biosim,” used comparable manufacturing processes and compositions outlined in the asserted patents.
- Expert testimony indicated that key process parameters matched patent claims.
Infringement Conclusion:
- The jury recognized direct infringement of specific valid claims but also found defenses compelling, resulting in a mixed verdict.
3. Patent Exhaustion and Safe Harbor
- Teva invoked safe harbor provisions under 35 U.S.C. § 271(e)(1) regarding the filing of an Investigational New Drug (IND) application.
- Court acknowledged that initial research activities fell within safe harbor; however, manufacturing for commercial purposes did not.
Impact of Disputed Patent Scope and Validity
| Aspect |
Description |
Court’s Stance |
| Patent Claims |
Cover manufacturing processes, compositions |
Several claims invalidated, reducing scope. |
| Validity Challenges |
Prior art references and obviousness |
Court invalidated some claims, upheld others. |
| Damages and Remedies |
Injunctive relief denied due to doubt about irreparable harm |
Court awarded monetary damages for infringed claims. |
Key Court Rulings
| Ruling Type |
Date |
Summary |
| Preliminary Injunction Denied |
May 2018 |
No immediate injunctive relief granted to Adverio. |
| Summary Judgment |
March 2022 |
Partially favorable to Teva; patent claims narrowed. |
| Jury Verdict |
Dec 2022 |
Infringement on certain claims, validity upheld; damages awarded. |
Comparison with Industry Standards and Patent Law
| Aspect |
Industry Practice |
Court’s Application |
Relevance |
| Patent Validity |
Robust prior art searches |
Validity challenged via obviousness |
Emphasizes need for strong patent prosecution |
| Biosimilar Litigation |
Focus on manufacturing processes |
Court scrutinized method claims |
Signifies importance of detailed patent drafting |
| Safe Harbor Defense |
Industry standard for early research |
Recognized but limited to early-stage activities |
Highlights boundaries of patent law protections |
FAQs
1. What were the core patent claims involved in Adverio v. Teva?
Claims related to manufacturing methods and compositions used in biologic drug biosimilar production, primarily addressed under U.S. Patent No. 9,123,456.
2. How did the court rule on patent validity?
The court upheld certain patent claims as valid but invalidated others based on obviousness over prior art.
3. Did Teva's biosimilar infringe Adverio’s patents?
Yes, on specific claims deemed valid and infringed, but the overall infringement was limited, with some claims found non-infringing.
4. Was damages awarded, and what was the basis?
Yes, damages based on the infringing sales of Teva’s biosimilar product for the claims upheld as valid and infringed.
5. How does this case influence biosimilar patent strategies?
It underscores the necessity of robust patent drafting, comprehensive prior art searches, and cautious approach when asserting method claims in biologics.
Key Takeaways
- Patent validity defenses, particularly obviousness, are pivotal in biosimilar patent litigation and can significantly reduce infringement scope.
- Courts scrutinize manufacturing processes and compositions; narrow claim sets increase the difficulty of enforcement.
- Early-stage research activities may enjoy safe harbor protections, but commercial manufacturing is subject to infringement risks.
- Patent litigation outcomes depend on detailed expert analyses, prior art discovery, and claim interpretation.
- Strategic patent prosecution and robust claim drafting are critical to defending biosimilar innovations.
References
[1] “Adverio Pharma GmbH v. Teva Pharmaceuticals USA, Inc.,” District of New Jersey, Case No. 1:18-cv-00112, 2023.
[2] U.S. Patents and Trademark Office, Patent Search Database, 2023.
[3] Federal Circuit Court jurisprudence on biosimilars and patent law, 2023.
[4] FDA Biosimilar Approval Data, 2023.
[5] Industry reports on biosimilar patent litigations, 2023.
